Open Access

ARTICLE

TUG1 Indicate Unfavorable Prognosis of Gastric Cancer for Promoting Proliferation, Migration and Multidrug Resistance

Yuan Liu^1,2,#, Yun Jia³, Bing Zhang², Anwen Liu^1,*

1 The Second Affiliated Hospital of Nanchang University, Jiangxi Key Laboratory of Clinical and Translational Cancer Research, Nanchang, 330006, China
2 The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, 330006, China
3 The First People’s Hospital of Xiangyang, Xiangyang, 441000, China

* Corresponding Author: Anwen Liu. Email:
# First author

Oncologie 2021, 23(1), 61-72. https://doi.org/10.32604/Oncologie.2021.015906

Received 22 January 2021; Accepted 25 February 2021; Issue published 30 March 2021

Abstract

Gastric cancer (GC) is the most common digestive system malignant tumor and second most common cause of cancer-related death. Even for the early gastric cancer, after radical operation, perioperative and postoperative chemotherapy the recurrence and metastasis are also high. 5-year overall survival of all GC patients is only 10–15%. Chemo-resistance still poses a major obstacle to successful treatment of GC. The aberrant expression of TUG1 (Taurine Upregulated Gene 1) was closely related to chemo-resistance and metastasis in many cancers. Here we over-expressed TUG1 in GC cell line SGC-7901 and MGC-803. We compared the migration ability and sensitivity of cisplatin (CDDP), doxorubicin(ADM), 5-fluorocrail(5-Fu) on SGC-7901, SGC-7901/TUG1 and MGC-803, MGC-803/TUG1. The TUG1 induced the multi-drugs resistant and promoted the mobility of GS cell. Furthermore, we investigate the clinical significance of TUG1 and evaluate its prognostic value in patients with GC. The expression of TUG1 was positive in GC tissues and was significantly correlated with tumor size and lymphatic metastasis. Our findings demonstrate the TUG1 may function as a protooncogene and potential biomarker of GC.

---

Keywords

---